[go: up one dir, main page]

DOP2023000242A - Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 - Google Patents

Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8

Info

Publication number
DOP2023000242A
DOP2023000242A DO2023000242A DO2023000242A DOP2023000242A DO P2023000242 A DOP2023000242 A DO P2023000242A DO 2023000242 A DO2023000242 A DO 2023000242A DO 2023000242 A DO2023000242 A DO 2023000242A DO P2023000242 A DOP2023000242 A DO P2023000242A
Authority
DO
Dominican Republic
Prior art keywords
oxopiperazin
carboxamides
inhibitors
disorders
cycloheteroalkyl
Prior art date
Application number
DO2023000242A
Other languages
English (en)
Inventor
Liu Jian
Liu Hong
Arasappan Ashok
M Bell Ian
M Cox Jason
J Iii Kelly Michael
Eric Layton Mark
A Shah Akshay
D Vanheyst Michael
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of DOP2023000242A publication Critical patent/DOP2023000242A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los nuevos compuestos de fórmula estructural (I), y las sales farmacéuticamente aceptables de los mismos, son inhibidores de la actividad de los canales Nav1.8 y pueden ser útiles en el tratamiento, prevención, gestión, mejoría, control y supresión de enfermedades mediadas por la actividad de los canales Nav1.8. Los compuestos de Fórmula I pueden ser útiles en el tratamiento, prevención o gestión de trastornos de dolor, trastornos de tos, trastornos de picazón aguda y trastornos de picazón crónica.
DO2023000242A 2021-05-07 2023-11-01 Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8 DOP2023000242A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163185637P 2021-05-07 2021-05-07
US202163286691P 2021-12-07 2021-12-07
PCT/US2022/027763 WO2022235859A1 (en) 2021-05-07 2022-05-05 Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors

Publications (1)

Publication Number Publication Date
DOP2023000242A true DOP2023000242A (es) 2023-12-15

Family

ID=81927873

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000242A DOP2023000242A (es) 2021-05-07 2023-11-01 Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8

Country Status (17)

Country Link
US (1) US20220380338A1 (es)
EP (1) EP4334293A1 (es)
JP (1) JP7522943B2 (es)
KR (1) KR20240005878A (es)
AU (1) AU2022270115A1 (es)
BR (1) BR112023023239A2 (es)
CA (1) CA3217565A1 (es)
CL (1) CL2023003295A1 (es)
CO (1) CO2023015096A2 (es)
CR (1) CR20230519A (es)
DO (1) DOP2023000242A (es)
EC (1) ECSP23083881A (es)
IL (1) IL308215A (es)
MX (1) MX2023013146A (es)
PE (1) PE20250021A1 (es)
TW (1) TWI827037B (es)
WO (1) WO2022235859A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022270061A1 (en) * 2021-05-07 2023-11-16 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
AU2023257313A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
IL316422A (en) 2022-04-22 2024-12-01 Vertex Pharma Heteroaryl compounds for pain treatment
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
JP2025513452A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
CN117645533B (zh) * 2023-10-20 2024-10-11 泰州精英化成医药科技有限公司 一种4-(三氟甲基)环己酮的合成方法
WO2025090465A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2025090516A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing compounds for treating pain and solid forms thereof
WO2025090511A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Methods of preparing modulators of sodium channels and solid forms of the same for treating pain
WO2025090480A1 (en) 2023-10-23 2025-05-01 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
CN117567323A (zh) * 2023-10-30 2024-02-20 湖北泰盛化工有限公司 一种(s)-4-氯-2-((甲氧基羰基)氨基)丁酸乙酯的制备方法
US20250186419A1 (en) 2023-12-07 2025-06-12 Vertex Pharmaceuticals Incorporated Dosing regimens for treating pain

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52122392A (en) * 1976-04-07 1977-10-14 Sangyo Kagaku Kenkyu Kyokai Novel antibacterials
WO2005061470A1 (en) * 2003-12-18 2005-07-07 Cv Therapeutics, Inc. 1-akan-2-ol substituted piperazine and piperidine compounds
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
WO2009049180A2 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
US8779197B2 (en) 2007-10-11 2014-07-15 Vertex Pharmaceuticals Incorporated Aryl amides useful as inhibitors of voltage-gated sodium channels
CA2771472A1 (en) * 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Oxopiperazine derivatives for the treatment of pain and epilepsy
US8889863B2 (en) * 2010-07-16 2014-11-18 Vanderbilt University Stereoselective methods, catalysts and intermediates for the synthesis of (−)-Nutlin-3 and related compounds
GEP20217286B (en) 2013-01-31 2021-08-25 Vertex Pharma Pyridone amides as modulators of sodium channels
CA2898650C (en) 2013-01-31 2021-09-07 Vertex Pharmaceuticals Incorporated Quinoline and quinoxaline amides as modulators of sodium channels
BR112015018284B1 (pt) 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
AU2014290411B2 (en) 2013-07-19 2018-11-15 Vertex Pharmaceuticals Incorporated Sulfonamides as modulators of sodium channels
JP6463580B2 (ja) 2013-12-13 2019-02-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
WO2017209322A1 (ko) 2016-05-31 2017-12-07 한림대학교 산학협력단 5원 헤테로사이클릭 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
EP3625214B1 (en) 2017-05-16 2022-07-06 Vertex Pharmaceuticals Incorporated Deuterated pyridone amides and prodrugs thereof as modulators of sodium channels
TN2020000001A1 (en) 2017-07-11 2021-10-04 Vertex Pharma Carboxamides as modulators of sodium channels
JP2021504466A (ja) * 2017-11-23 2021-02-15 オスロ ウニヴェルシティ ホスピタル ホーエフ 頻脈の治療
CN112469725A (zh) * 2018-05-25 2021-03-09 维纳拓尔斯制药公司 青霉素结合蛋白抑制剂
WO2020092667A1 (en) 2018-11-02 2020-05-07 Merck Sharp & Dohme Corp. 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
EP3873468A4 (en) * 2018-11-02 2022-10-26 Merck Sharp & Dohme LLC 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS
EP4065587A4 (en) * 2019-11-26 2023-12-27 Venatorx Pharmaceuticals, Inc. PENICILLIN BINDING PROTEIN INHIBITORS
CA3182633A1 (en) * 2020-06-17 2021-12-23 Ashok Arasappan 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
KR20230026405A (ko) * 2020-06-17 2023-02-24 머크 샤프 앤드 돔 엘엘씨 Nav1.8 억제제로서의 5-옥소피롤리딘-3-카르복스아미드

Also Published As

Publication number Publication date
PE20250021A1 (es) 2025-01-07
TWI827037B (zh) 2023-12-21
BR112023023239A2 (pt) 2024-01-23
IL308215A (en) 2024-01-01
ECSP23083881A (es) 2023-12-29
TW202308999A (zh) 2023-03-01
EP4334293A1 (en) 2024-03-13
CR20230519A (es) 2024-01-19
WO2022235859A1 (en) 2022-11-10
MX2023013146A (es) 2023-11-28
CA3217565A1 (en) 2022-11-10
CO2023015096A2 (es) 2023-11-20
KR20240005878A (ko) 2024-01-12
CL2023003295A1 (es) 2024-07-12
AU2022270115A1 (en) 2023-11-16
US20220380338A1 (en) 2022-12-01
JP2024515895A (ja) 2024-04-10
JP7522943B2 (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
CO2023015096A2 (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8
CO2022018295A2 (es) 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8
MX2021005154A (es) 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8.
MX2022015580A (es) 5-oxopirrolidin-3-carboxamidas como inhibidores de nav1.8.
MX2022015579A (es) 2-oxo-oxazolidin-5-carboxamidas como inhibidores de nav1.8.
MX2023013147A (es) Aril 3-oxopiperazin carboxamidas y heteroaril 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
MX2022015857A (es) Compuestos de dihidroquinolin sulfonamida de heteroalquilo.
MX386542B (es) Derivados de la 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmacéuticas que los incluyen.
CO2022016153A2 (es) Inhibidores de il4i1 y métodos de uso
MX2021016055A (es) Formulaciones y métodos de parasiticidas de isoxazolina para el tratamiento de la blefaritis.
ZA202404839B (en) Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof
ECSP22011746A (es) Agentes antipalúdicos
CL2022000781A1 (es) Tratamientos cognitivos medicinales
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
CO2024017734A2 (es) Compuesto novedoso y composición farmacéutica que comprende la misma como ingrediente activo
EA202193211A1 (ru) Лечение синуклеопатий
MX2021001502A (es) Tratamiento de verrugas.
CL2024003468A1 (es) Inhibidores de ripk1 y métodos de uso.
AR125786A1 (es) CICLOALQUIL 3-OXOPIPERAZIN CARBOXAMIDAS Y CICLOHETEROALQUIL 3-OXOPIPERAZIN CARBOXAMIDAS COMO INHIBIDORES DE Naᵛ1.8
MX2023010016A (es) Derivado de pirimidina con actividad inhibidora contra las proteina cinasas y composicion farmaceutica terapeutica que incluye el mismo.
EA201900418A1 (ru) Средство для терапии раневых или ожоговых поражений кожи
MX2020007183A (es) Inhibidores de ret9 y vegfr2.